Why the study?
BCOR-CCNB3 fusion sarcoma is an emerging subgroup of undifferentiated small round cell sarcoma representing a rare entity among primary malignant bone tumors.
Population
One 12-year-old boy with BCOR-CCNB3 fusion sarcoma in the proximal tibia
Design
Case report and literature review
Follow-up
12 months after completion of adjuvant chemotherapy
Authors
Loading...
Raises awareness for rare BCOR-CCNB3 sarcoma in pediatric knee pain; leaves open optimal management strategies.
This case report describes the successful treatment of a rare BCOR-CCNB3 sarcoma of the proximal tibia using tumor resection and Ewing sarcoma protocol chemotherapy.
Suzuki et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: